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Treatments targeting metabolic abnormalities in children with autism are limited. Previously we reported that a nutritional
treatment significantly improved glutathione metabolism in children with autistic disorder. In this study we evaluated changes in
adaptive behaviors in this cohort and determined whether such changes are related to changes in glutathione metabolism. Thirty-
seven children diagnosed with autistic disorder and abnormal glutathione and methylation metabolism were treated with twice
weekly75𝜇g/Kgmethylcobalaminandtwicedaily400𝜇gfolinicacidfor3monthsinanopen-labelfashion.TheVinelandAdaptive
Behavior Scale (VABS) and glutathione redox metabolites were measured at baseline and at the end of the treatment period. Over
the treatment period, all VABS subscales significantly improved with an average effect size of 0.59, and an average improvement in
skills of 7.7 months. A greater improvement in glutathione redox status was associated with a greater improvement in expressive
communication,personalanddomesticdailylivingskills,andinterpersonal,play-leisure,andcopingsocialskills.Age,gender,and
history of regression did not influence treatment response. The significant behavioral improvements observed and the relationship
between these improvements to glutathione redox status suggest that nutritional interventions targeting redox metabolism may
benefit some children with autism.
1. Introduction
Autism is a neurodevelopmental disorder characterized by
significant impairment in reciprocal social interaction and
communication as well as restricted interests and repetitive
behaviors. An estimated 1 of 88 individuals in the United
States is affected with an autism spectrum disorder (ASD)
[1]. Although several genetic syndromes are associated with
ASD, all of these genetic syndromes together only account
for a minority of ASD cases [2]. Other areas of novel research
have concentrated on systemic physiological abnormalities,
such as mitochondrial dysfunction [3, 4], oxidative stress [5–
7], and inflammation/immune dysregulation [8–10]. These
novel areas of research have substantially grown over the last
decade [11]. These emerging areas of research have provided
a new understanding of the diverse mechanisms involved in
ASD and have promoted the idea that the autism spectrum is
composed of several subgroups or endophenotypes [12].
Several lines of evidence support the notion of an
ASD endophenotype with abnormal redox and methylation
metabolism. In two case-control studies we reported that
r e d o xa n dm e t h y l a t i o nm e t a b o l i s mi nc h i l d r e nd i a g n o s e d
with autism was abnormal compared to that of unaffected
control children [6, 13]. Briefly, the mean ratio of plasma
S-adenosyl methionine (SAM) to S-adenosyl homocysteine
(SAH), a reflection of cellular methylation capacity, was2 Autism Research and Treatment
significantly reduced. Also, the mean concentration of free
reduced glutathione (GSH), the major intracellular antiox-
idant and mechanism for detoxification, was also signifi-
cantly decreased and the oxidized disulfide form of glu-
tathione (GSSG) was significantly increased. This imbalance
in reduced as compared to oxidized glutathione resulted in
a 2-fold reduction in the GSH/GSSG redox ratio, an index
known as the glutathione redox status. Several precursors
for methylation and glutathione synthesis were also lower
in the autistic children suggesting an insufficiency in the
production of methylation and glutathione metabolites, at
least in a subgroup of ASD children. In addition, we have
also demonstrated that GSH is significantly reduced in the
cytosol and isolated mitochondria from lymphoblastoid cell
lines and fresh peripheral blood mononuclear cells derived
from children with autistic disorder (AD) [14, 15].
Theglutathioneprovidestheessentialintracellularreduc-
ing environment required for normal immune function,
detoxification capacity, redox-sensitive enzyme activity, and
membrane redox signaling [16–20]. Oxidative stress occurs
when antioxidant defense mechanisms fail to counterbal-
ance reactive oxygen species generated from endogenous
oxidative metabolism or from prooxidant environmental
exposures.Thenotionthatabnormalglutathionemetabolism
is associated with oxidative cellular damage is consistent with
studies from our laboratory which demonstrate an increase
in oxidative damage to protein and DNA in peripheral
blood mononuclear cells and postmortem brain derived
from ASD individuals [15, 21]. Several recent reviews and
researchstudiesalsolendsupporttothehypothesisthatredox
imbalance and oxidative stress may be a contributing factor
to autism pathophysiology [6, 22].
These findings have particular clinical relevance since
abnormalities in redox metabolism are potentially amenable
to treatment. Glutathione is a tripeptide of cysteine, glycine,
and glutamate that is synthesized de novo in all cells.
Glutathione synthesis is tightly connected to methylation
metabolism where it derives its cysteine precursor. As both
methylationandglutathionemetabolismhavebeenshownto
be abnormal in children with ASD and due to the fact that
abnormal methylation metabolism will result in a depletion
of the precursors needed for glutathione production, we
p r e v i o u s l yc o n d u c t e da no p e n - l a b e li n t e r v e n t i o nt r i a lw h e r e
targeted metabolic cofactors for methylation and glutathione
metabolismwereprovided.Specifically,inourpreviousstudy,
we determine if glutathione redox status could be improved
with a three-month intervention of subcutaneously injected
methylcobalamin and oral folinic acid in children with AD
and metabolic evidence of abnormal methylation and glu-
tathione metabolism [23]. Although we measured adaptive
behaviorusingtheVinelandAdaptiveBehaviorScale(VABS)
during the trial, this behavioral data has not been previously
reported.Wenowreportthechangeincommunication,daily
living, and social skills domains of the VABS associated with
the three-month intervention as well as investigate whether
improvement in glutathione redox status was related to any
change in VABS behavior scores.
Screened and met 
inclusion criteria  
N = 65 
Entered clinical trial
N = 48 
Normal metabolic profile, N = 17
Lost to follow-up, N = 4
Started treatment
N = 44 
Discontinued treatment
Uncomfortable with injections, N = 2
Hyperactivity and reduced sleep, N = 2
Completed treatment
N = 40 
Did not complete second behavioral 
evaluation, N = 3
Behavioral data for 
analysis, N = 37
Figure 1: Flowchart of patients who met inclusion criteria for the
study.
2. Methods and Materials
2.1.Participants. Forty-eightchildrenwithADwereenrolled
inanopen-labeltrialtotestwhetherathree-monthtreatment
of methylcobalamin (methyl B12) and folinic acid would
improve glutathione synthesis as well as adaptive behavior.
Inclusion criteria were a diagnosis of AD as defined by the
Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV) criteria (299.0) and a Childhood Autism
Rating Scales (CARS) score greater than 30. Exclusion cri-
teria included Asperger’s disorder, pervasive developmental
disorder-not otherwise specified (PDD-NOS), genetic disor-
ders,epilepsy,severegastrointestinalsymptoms,recentinfec-
tions, and/or current use of high-dose vitamin or mineral
supplements (i.e., above the recommend daily allowance).
Metabolic and behavioral assessments were conducted at
baseline and at the end of the 3-month intervention. A nurse
contacted each family every two weeks to ensure compliance
and monitor adverse effects.
Figure 1 provides a flowchart of the patients who met cri-
teriaforpossibleinclusioninthestudy.Inordertodetermine
if abnormal redox metabolism could be improved with the
intervention,weselectedchildrenwithabnormalglutathione
redox status and methylation capacity for entry into the
study. Normal glutathione redox status and methylation
capacity were defined by measuring these same metabolites
in typically developing control children. Sixty-five autistic
childrenmettheinclusioncriteriaandwereinitiallyscreened
for metabolic evidence of abnormal methylation capac-
ity (SAM/SAH < 3.0) and glutathione redox metabolism
(GSH/GSSG < 6.0). Of these, 48 (75%) children were found
to have both abnormal methylation capacity and glutathione
redox metabolism, thus meeting metabolic qualifications forAutism Research and Treatment 3
inclusion. The remaining 17 (25%) were excluded because
their baseline metabolic profile was within normal range.
Fourchildrendroppedoutduringthestudyandanotherfour
children were lost to follow-up. Two children dropped out
o ft h es t u d yb e c a u s et h ep a r e n t sw e r eu n c o m f o r t a b l eg i v i n g
the methylcobalamin injections and 2 children dropped out
because of hyperactivity and reduced sleep. For the four that
were lost to follow-up, every attempt was made to contact
the family but they either did not response to such requests
or moved out of the area and could not return for follow-
up. Of the 40 remaining children who completed the study,
three of the parents did not complete the second behavioral
evaluation, leaving 37 children who completed both the
interventionandthebehavioralevaluation.Characteristicsof
t h ec h i l d r e nt h a tc o m p l e t e dt h es t u d ya r eg i v e ni nTable 1.
A d v e r s ee ff e c t sw e r em i n i m a lw i t ho c c a s i o n a lr e p o r t so f
hyperactivity, as summarized in our previous study [23]a n d
below. All parents signed informed consent approved by the
Institutional Review Board at the University of Arkansas for
Medical Sciences.
2.2. Intervention. Methylcobalamin was provided as a sterile
injectable liquid from Hopewell Compounding Pharmacy
(Hopewell, NJ). Tuberculin syringes fitted with a 1/4 inch 31
gauge needle were prefilled with 75𝜇g/Kg methylcobalamin
and prepared individually based on each child’s weight. A
demonstration and instructions for the sterile subcutaneous
injection of methylcobalamin in the fatty tissue of the but-
tocksweregiventoallparents.Parentswereinstructedtogive
methylcobalamin every third day for 3 months. Folinic acid
(400𝜇g) obtained from Custom Compounding (Little Rock,
AR) was administered orally twice each day as a powder
mixed with a convenient food.
The subcutaneous injectable route of administration of
methylcobalaminwasselectedbasedonpreliminaryobserva-
tio n stha ti tr es ul t edinim p r o v emen tins peec ha ndcogni tio n
[13] and the potential for support of methionine synthase
activity under conditions of oxidative stress by substituting
for the oxidized inactive form of coenzyme B12 [Cob (II)].
Folinic acid (5-formyltetrahydrofolate) was selected in light
o ft h ef a c tt h a ti ti sa b s o r b e da st h er e d u c e dm e t a b o l i t e
is rapidly polyglutamated and is more readily available for
folate-dependent reactions than the synthetic vitamin form
of folic acid. In our previous study, we demonstrated that this
treatment significantly improved GSH and GSSG concentra-
tions and glutathione redox status (i.e., the GSH/GSSG ratio)
[23].
2.3. Glutathione Measurement. Fasting blood samples were
collected into EDTA-Vacutainer tubes and immediately
chilled on ice before centrifuging at 4000×gf o r1 0m i n u t e s
at 4
∘C. To prevent metabolite interconversion, the ice-cold
samples were centrifuged within 15 minutes of the blood
collectionandtheplasmastoredat−80
∘Cuntilhigh-pressure
liquid chromatography quantification within 2 weeks after
receipt. Details of the methodology for high-pressure liquid
chromatographywithelectrochemicaldetectionandmetabo-
lite quantitation have been previously described [24, 25].
Table 1: Characteristics of the 37 participants with autistic disorder
who completed the trial.
Gender (% male) 81%
Age (mean ± standard deviation) 5.1 ± 1.4 years
Regression (% regression) 35%
Childhood Autism Rating Scale score
(mean ± standard deviation)
39.2 ± 7.8
2.4. Behavioral Evaluation. The VABS (1st Edition) is a
validated parent interview that provides a numerical score
for adaptive functioning in the domains of communication,
socialization, and daily living skills which has been shown to
have good reliability and validity [26]. Nine subscales repre-
sented these three domains, specifically receptive, expressive,
and writing communication, personal, domestic, and com-
munity daily living skills, and interpersonal relations, play-
leisure, and coping skills. Raw scores were used in the statis-
tical analysis while age equivalent scores are used to illustrate
themagnitudeofthechangesinbehavioraldevelopmentover
the treatment period and domain scaled scores are provided
as a comparison of the participant sample to the general
p o p u l a t i o n .H i g h e rr a w ,a g ee q u i v a l e n t ,a n ds c a l e ds c o r e s
representedbetterperformanceonthesemeasures.TheVABS
was administered by a trained nurse at the baseline visit and
again at the end of the treatment period.
2.5. Statistics. Mixed-effects regression models were con-
ducted via SAS version 9.3 (Cary, NC) “glmmix” procedure
[27] .Ra ws c o r e sw e r eu s e di nt h es t a t i s t i c a la n a l y s i st or e p r e -
sent the change in behavior over the intervention period. A
s i m i l a ra p p r o a c hw a su s e di no u rr e c e n ts t u d yo nt h ee ff e c t
of sapropterin treatment in children with ASD [28]. Raw
scores were used due to the fact that transformation of raw
scores into scaled scores is not statistically valid to follow
c h a n g e si na d a p t i v eb e h a v i o re s p e c i a l l yw h e ne x a m i n i n gt h e
moderating effect of a biomarker on the change in behavior
and especially when there is no reference control group. For
example, many children with ASD have slow or stagnant
development, so their development may not change over
a typical three-month interval. With an intervention, their
development may approach the rate of a typically developing
child. However, a child whose development changes over
the three-month period at a rate equal to that of a typically
developing child would have a stable unchanging scaled
score. Thus, in such a case, the scaled score would appear
to reflect no developmental gains over the treatment period
even though the child was making developmental gains.
Since the null hypothesis is that there is no change over
the treatment period, an unchanging scaled score would
not be statistically significant even though it would indicate
developmental progress.
The first statistical model included a linear effect of time
on raw scores. A random intercept was used to account for
each individual’s symptom level. Two-tailed alpha of 0.05
w a su s e di na l la n a l y s e s .I nt h e s ei n i t i a lm o d e l sw et e s t e d
whetherage,gender,and/orahistoryofregressioninfluenced4 Autism Research and Treatment
Table 2: Age equivalent scores from the Vineland Adaptive Behavior Scales at baseline before and after 3-month intervention with
methylcobalamin and folinic acid. The change in age equivalent scores with 95% confidence interval (CI) is also given. The overall average of
all subscales is also given in the last row of the table.
Vineland subscale Baseline age equivalent (months)
(mean ± SE)
Postintervention age equivalent
(months) (mean ± SE)
Change in age equivalent
(months) (mean; 95% CI)
Receptive language 23.1 ± 1.8 31.4 ± 3.4 8.3 (2.9, 13.7)
Expressive language 20.6 ± 1.9 27.5 ± 2.9 6.0 (3.3, 9.4)
Written language 40.5 ± 3.8 46.7 ± 4.0 6.2 (3.4, 9.0)
Personal skills 30.5 ± 2.3 40.5 ± 3.8 10.0 (3.8, 16.2)
Domestic skills 30.3 ± 4.1 39.3 ± 5.9 9.0 (−1.4, 19.4)
Community skills 32.9 ± 2.9 36.1 ± 3.8 2.0 (−3.0, 6.9)
Interpersonal skills 18.7 ± 2.7 24.1 ± 3.9 5.4 (0.0, 10.9)
Play/leisure skills 22.0 ± 4.5 34.0 ± 4.1 12.0 (4.1, 19.6)
Coping skills 25.8 ± 2.5 34.3 ± 4.0 11.5 (4.9, 18.0)
Overall skills 26.6 ± 2.3 34.3 ± 3.6 7.7 (3.4, 12.0)
t h ec h a n g ei nt h eo u t c o m em e a s u r e .T oi l l u s t r a t et h er e l a t i v e
strength of the effect we provide the Cohen’s 𝑑 effect size
for each significant change in outcome variables. Next we
determined whether baseline and/or change in glutathione
redox status (i.e., the free reduced-to-oxidized glutathione
ratio) moderated changes in the outcome variables. The glu-
tathione redox status was investigated because it significantly
changed with treatment in our previous study [23]. We did
not investigate the moderating effect of other metabolites
as multiple statistical tests would have increased our type I
error rate. We conducted two sets of analyses; one examined
the moderating effect of the overall glutathione redox status
and another that examined the moderating effect of the
change in glutathione redox status over the treatment period.
The former analysis was conducted to determine whether
glutathione redox status in general was related to VABS
scores,whilethelatteranalysiswasconductedtodetermineif
the change in glutathione status was related to the change in
VABS scores over the treatment period. Age, gender, and/or
regression factors were included in the analyses examining
the moderating effect of glutathione if they were significant
in the initial model.
3. Results
3.1. Behavior Change over the Intervention Period. The VABS
was used to examine the impact of the intervention on mea-
sures of core behaviors associated with autism. The changes
in VABS subscales with treatment were not influenced by
gender, age, or history of regression, and neither gender nor
history of regression was related to overall VABS subscale
scores. Age was significantly related to overall raw scores for
all subscales, except for interpersonal and coping skills.
Significant increases were found in all VABS subscale
scores, including receptive (𝐹(1,36) = 11.90,𝑃 = 0.001;𝑑 =
0.59), expressive (𝐹(1,36) = 32.80,𝑃 < 0.0001;𝑑 = 0.97),
and written (𝐹(1,36) = 11.07, 𝑃 < 0.005; 𝑑 = 0.56)c o m -
munication skills, personal (𝐹(1,36) = 14.69,𝑃 < 0.0005;
𝑑 = 0.65), domestic (𝐹(1,36) = 4.85,𝑃 < 0.05;𝑑 = 0.37)a n d
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Figure 2: Histogram of actual age and age equivalents for the
Vineland Adaptive Behavior Scale subscales. Error bars depict
standard error.
community(𝐹(1,36) = 9.51,𝑃 < 0.005;𝑑 = 0.52)dailyliving
skills,andinterpersonal(𝐹(1,36) = 6.45,𝑃 < 0.05;𝑑 = 0.43),
play-leisure (𝐹(1,36) = 12.36,𝑃 = 0.001;𝑑 = 0.59), and
coping (𝐹(1,36) = 15.68,𝑃 = 0.0005;𝑑 = 0.66)s o c i a ls k i l l s .
To illustrate the magnitude of the change in develop-
ment with the intervention, Table 2 and Figure 2 present the
average age equivalent for all subscales before and after the
intervention. Table 2 also demonstrates the change in age
equivalent with the intervention including confidence inter-
vals. As evident from this table, many subscales, particularly
those with larger effect sizes, demonstrate large gains with
the three-month intervention. This is particularly true for
the communication domain where skills improved between
6.0 and 8.3 months, on average, and in the social skills
domain where skills improved between 5.4 and 12.0 months,
on average, over a three-month period.
Baseline pretreatment scores of the individual domains
a n do v e r a l lc o m p o s i t eo ft h eV A B S( m e a n( S D ) :c o m m u -
nication 65.4 (13.0); daily living skills 66.4 (13.4); social
skills 67.3 (9.3); adaptive behavioral composite 66.1 (9.3))
were found to be within the range of previously published
VABS scores for children with autistic disorder [15, 29].
FollowinginterventionallindividualdomainsandtheoverallAutism Research and Treatment 5
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Figure 3: Significant relationships between the change in the glutathione redox status (reduced-to-oxidized glutathione ratio) and change
in subscales of the Vineland Adaptive Behavior Scale (VABS) subscales. An improvement in glutathione redox status was associated with
improvement in (a) expressive communication (𝐹(1,33) = 9.66,𝑃 < 0.01), (b) personal daily living skills (𝐹(1,34) = 12.84,𝑃 = 0.001), (c)
domestic daily living skills (𝐹(1,34) = 4.69,𝑃 < 0.05), (d) interpersonal social skills (𝐹(1,34) = 10.47,𝑃 < 0.005), (e) play-leisure social
skills (𝐹(1,34) = 8.16,𝑃 < 0.01), and (f) coping social skills (𝐹(1.34) = 6.09,𝑃 < 0.05). The moderating effect of glutathione redox status on
the VABS subscale is provided in the graph as a representation of the relationship between the variables. Since the linear models examining
the moderating effect of glutathione redox status on the VABS subscale takes into account age, simple correlation coefficients would not be
accurate for inclusion in the graphs.
composite of the VABS markedly increased (Mean (SD):
communication72.1(15.7);dailylivingskills76.0(18.0);social
skills 75.6 (16.5); adaptive behavioral composite 73.8 (17.4)).
3.2. Relation between Behavior and Glutathione Redox Status.
The overall glutathione redox status was not related to
VABS subscales, indicating that overall development did not
appear to be related to overall glutathione redox status. In
order to determine whether changes in VABS subscales were
related to changes in glutathione redox status, we examined
whether the glutathione redox status moderated the change
in the VABS subscales. We found that glutathione redox
status moderated expressive communication (𝐹(1,33) =
9.66,𝑃 < 0.01), personal (𝐹(1,34) = 12.84,𝑃 = 0.001)
and domestic (𝐹(1,34) = 4.69,𝑃 < 0.05)d a i l yl i v i n gs k i l l s ,
and interpersonal (𝐹(1,34) = 10.47,𝑃 < 0.005), play-leisure
(𝐹(1,34) = 8.16,𝑃 < 0.01), and coping (𝐹(1,34) = 6.09,
𝑃 < 0.05) social skills such that a greater increase in the glu-
tathione redox status (i.e., greater improvement in glu-
tathione)wasassociatedwithagreaterimprovementinVABS
subscale scores (see Figure 3).
3.3. Adverse Effects. The adverse effect rates are outlined in
Table 3. Out of the forty-four children that started the study
and were not lost to follow-up, 72% reported no adverse
effects of the treatment. For the four children that dropped
out of the study two children (5%) dropped out because
the parents were uncomfortable giving the methylcobalamin
Table3:Adverseeffectsreportedofinterventionwithmethylcobal-
aminandfolinicacid.All44childrenwhoenteredthestudybutwere
not lost to follow-up were included.
Adverse effect % (𝑁)
Hyperactivity 14% (6)
Reduced sleep 7% (3)
Discomfort with injections 5% (2)
Insomnia 2% (1)
Impulsivity 2% (1)
Irritability 2% (1)
injections and 2 children (5%) dropped out because of
hyperactivity and reduced sleep. Of the 4 families who
reported hyperactivity but did not drop out of the study, the
hyperactivityresolvedwithdecreasingthefolinicaciddoseto
400𝜇gp e rd a y .
4. Discussion
This intervention trial was undertaken to determine whether
a nutritional intervention consisting of treatment with
metabolic precursors for methionine and glutathione syn-
thesis would improve autism symptoms in children with
AD. Children meeting the inclusion criteria were initially
screened for metabolic evidence of abnormal methylation
capacity and glutathione redox status as an indication of6 Autism Research and Treatment
potentialbenefitfromtheintervention.Ourgoalwastodeter-
mine whether nutritional support with precursors for the
abnormalmetabolicpathwayscouldresultinimprovementin
ASD associated behavior as measured by the VABS. Overall,
significant improvement was noted on all subscales of the
VABS during the three-month intervention. In addition,
improvement on several VABS subscales, including those
related to communication and social skills, was related to
the improvement in glutathione redox status. Overall, this
studyprovidespreliminaryevidencethattargetednutritional
support in children with AD who have metabolic abnor-
malities in glutathione and methylation pathways may be
associatedwithimprovementsincertainbehaviorsassociated
with ASD, at least in a subset of AD children. In addition, a
low rate of adverse effects with methylcobalamin and folinic
acid treatment indicates that these supplements are safe and
warrants further study as an intervention.
4.1.BehavioralImprovementswithIntervention. Asimpleand
safe nutritional intervention of methylcobalamin and folinic
acid resulted in significant increases in VABS scores for all
domains, including daily living, social, and communication
skills, with an average effect size of 0.59, which is in the
medium-to-large range. In fact, even the smallest effect size
(domestic daily living skills, 𝑑 = 0.37)w a si nt h em e d i u m
range and the largest effect size (expressive language skills,
𝑑 = 0.97) was in the very large range. When considering
changes in age equivalent skills over the treatment period, it
was found that skills improved an average of 7.7 months over
the three-month treatment period, with the lower end of the
range being an average gain of 2.0 months for community
daily living skills to the higher end of the range being an
average gain of 12.0 months improvement for play-leisure
skills.However,whenweexaminetheoverallchangeinscaled
scoresacrossthethree-monthtreatmentperiod,wefindthat,
on average, the scaled score for the individual domains and
theadaptivebehavioralcompositeattheendofthetreatment
were still well below the average for typically developing
children. In fact, these scaled scores were, on average, at the
very lower end of normal range. Thus, although significantly
improved, the behavior scores after treatment remained, on
average, at the very low end of normal and for many children
below the normal range. This suggests that further therapy
mayberequiredtopromotecontinuedimprovementthrough
continued nutritional treatment with metabolic precursors
over a prolonged time period, the addition of intensive
behavioral and educational therapy, or both.
4.2.TheRelationshipbetweenMetabolicandBehavioralChan-
ges. Change in glutathione redox status with treatment, but
not baseline glutathione redox status prior to treatment,
w a sf o u n dt ob er e l a t e dt oi m p r o v e m e n t si ns e v e r a lV A B S
subscales, including all of the subscales in the social skills
domain, two of three subscales in the daily living skills
domain, and one of the subscales in the communication
domain. Interestingly, many of the VABS subscales that were
related to glutathione redox status were also subscales that
demonstrated large effect sizes and larger age equivalent
gains (e.g., personal daily living skills and play-leisure and
coping social skills). This suggests that the marked changes
in behaviors observed in these particular subscales were
not simply due to a placebo-effect and may indeed be
related to improvements in glutathione redox status over
the three-month treatment period, although we will have
to await double-blind placebo-controlled studies to validate
these findings. The lack of a relationship between overall
glutathione redox status and VABS scores most likely reflects
thepreselectionofchildrenwithlowglutathioneredoxstatus,
thus decreasing the overall range in glutathione redox status.
In our previous study, we demonstrated that this open-
label intervention significantly improved metabolites of glu-
tathionemetabolism,includingtotalandfreeGSHandGSSG
concentrations and the glutathione redox status (i.e., the
GSH/GSSG ratio) [23]. However, despite this improvement,
total and free GSH concentrations and the glutathione redox
status remained significantly below those of age-matched
control children. Additionally, methionine, SAM, and SAH
concentrationsdidnotsignificantlychangewiththeinterven-
tion despite the fact that both methylcobalamin and folinic
acid provide methyl groups for the methionine cycle. The
fact that the treatment improved but did not normalize
methionine,SAMandglutathioneconcentrationsmayreflect
ongoing metabolic compensation for incompletely resolved
oxidative stress. Thus, continued prooxidant conditions may
promote glutathione synthesis as the metabolic priority at
the expense of methionine transmethylation.Treatment with
methylcobalamin and folinic acid appears to have rescued
glutathionesynthesisinthiscohortofchildren,albeitincom-
pletely,attheexpenseoftransmethylationmetabolism.Given
t h ef a c tt h a ts o m eb e h a v i o r a li m p r o v e m e n t sw e r er e l a t e dt o
improvements in glutathionestatus, it is possible that longer-
term treatment or treatments that include additional precur-
sorsormethylcobalaminandfolinicacidathigherdosesmay
result in additional behavioral improvements. For example,
one recent open-label study demonstrated that high-dose
folinic acid demonstrated potential efficacy in children with
ASD [30] and another double-blind placebo controlled study
demonstrated that N-acetylcysteine, a glutathione precur-
sor, resulted in decreased irritability and improved social
function [31]. However, neither of these aforementioned
studies measured redox metabolism in order to determine
whether the observed behavioral effects were related to
changes in redox metabolism. Further studies will be needed
to determine the optimal combination of precursors for the
treatment of redox abnormalities in children with ASD.
4.3. The Use of Novel Interventions in Autism Spectrum Disor-
der. O u rfi n d i n g sa r ec o n s i s t e n tw i t hs m a l l e r[ 31, 32]a n d
larger [33] randomized control trials and large case series
[30]demonstratingthatnutritionalinterventionsforchildren
with ASD that target oxidative stress are associated with
improvements in core ASD symptoms [30, 31], sleep and gas-
trointestinal symptoms [32], and hyperactivity, tantruming
and parental impression of general functioning [33]. Besides
the methylcobalamin and folinic acid treatment used in this
study [23], the beneficial effect of nutritional treatments onAutism Research and Treatment 7
redox metabolism in children with ASD has been docu-
mented in a randomized control trial [33]a n dac r o s s -
sectional study [34]. Such studies suggest that glutathione
metabolism can be improved by vitamin and mineral [33]
and antioxidants, coenzyme Q10 and B vitamins supplemen-
tation [34], and sapropterin treatment [28]. Thus, although
there is evidence for nutritional treatments improving redox
metabolism and ASD symptoms and behaviors in children
with ASD, there is no specific established treatment for
correcting redox abnormalities in children with ASD and
the evidence for efficacy of nutritional treatments which
addressoxidativestressoncoreandassociatedASDbehaviors
is preliminary. Clearly more studies are needed to clarify
the potential beneficial effect of nutritional treatments for
children with ASD.
Thenutritionaltreatmentusedinthisstudyisconsidered,
by some, as a complementary and alternative medicine
(CAM) treatment [35]. However, CAM treatments refer to
a much wider variety of treatments, including nonnutri-
tional treatments such as acupuncture and homeopathy.
The prevalence of CAM in children diagnosed with a ASD
in western countries is estimated to be between 32% and
87% [35] which is believed to be much higher than CAM
therapiesusedintypicallydevelopingchildren[36].Children
with ASD with a greater number of medical and behavioral
problems receive more CAM treatments than those with
fewer medical and behavioral problems [37]. Parents believe
that most CAM-associated treatments are either helpful or
withouteffectbutnotharmful[35].Themainreasonsparents
c i t ef o rc h o o s i n gt ou s eC A Mf o rA S Da r ec o n c e r n sa b o u t
the safety and side effects of available medications for ASD
and a need to be involved in decisions involving care of
their child [38]. Because the majority of CAM therapies
are based on anecdotal evidence, there is a clear need for
clinical trials to evaluate the efficacy of these treatments
[35] .I na d d i t i o n ,i ts h o u l db en o t e dt h a tf o rA S D ,o fa l l
treatments considered CAM, nutritional treatments have the
most evidence for effectiveness and efficacy. Thus, it may
n o tb ep r o p e rt oc o n s i d e rn u t r i t i o n a lt r e a t m e n t s ,w h i c hh a v e
been used in mainstream medicine for over a century, as
equivalent to CAM treatments which have undergone much
fewer investigations and have less support for their use.
4.4. Limitations. The reported improvement in behavior
scores by parent report should be interpreted with caution
in an open-label trial because of expectation bias [38]. In
addition, without a control group it is difficult to know if,
andtowhatextent,developmentwouldhavechangedwithout
treatment. As this is a group with significant delays, it is
unlikely that they would have demonstrated typical gains
over the three-month period but it is possible they may
have shown some developmental progress. However, it is
r e a s s u r i n gt h a tas i g n i fi c a n tn u m b e ro fi m p r o v e m e n t sw e r e
moderated by improvements in glutathione metabolism,
suggesting that changes in metabolism were indeed related
to improvements in behavior.
This study prescreened and selected a subgroup of chil-
dren with ASD that demonstrated abnormal glutathione
redox status and methylation capacity as a means to increase
sensitivity to treatment. The broad heterogeneity of clinical
and behavioral symptoms in autistic children predicts that
no single treatment will benefit every autistic child. Thus,
the definition and characterization of subgroups of children
who respond positively or negatively to intervention will be
necessary to more sensitively identify those children who are
most likely to benefit from a given treatment or medication.
4.5. Conclusions. This study demonstrates that a three-
month treatment with methylcobalamin and folinic acid
is associated with significant improvements in behavioral
symptoms associated with ASD in a group of children with
AD and metabolic markers of abnormal redox and methyla-
tion metabolism. Our previous study demonstrated that this
treatment also improves metabolic markers of glutathione
metabolism in these same children. This provides conver-
gence of independent measures demonstrating the benefi-
cial effect of this simple and safe nutritional intervention.
Clearly this intervention requires further study in a double-
blind placebo-controlled trial to eliminate the potential bias
associated with an open-label study.
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